Recommended for AstraZeneca vaccine approval…Sk Chemical, Gene Matrix, United Pharm, and Abprobio?

[사진=게티이미지뱅크]

When an expert advisory group from the Ministry of Food and Drug Safety (MFDS) recommended conditional approval for AstraZeneca’s novel coronavirus infection (Corona 19) vaccine, AstraZeneca-related stocks are drawing attention.


AstraZeneca-related stocks are SK Chemicals, Gene Matrix, United Pharmaceuticals, and ABC Pro Bio.

As of the day, sk Chemicals rose 4.39% (18,500 won) to 439500 won, Jin Matrix rose 8.65% (1350 won) to 10,6950 won, and United Pharmaceuticals rose 6.23% (3050 won) to 50,000. 2,000 won, Abprobio traded at 1315 won, up 6.05% (75 won).

At a meeting held on the 31st of last month, the advisory group of the Ministry of Food and Drug Safety discussed the dosage, administration interval, and effectiveness and safety of AstraZeneca’s COVID-19 vaccine, the AstraZenecacovid-19 vaccine, and the effectiveness and safety for the elderly over the age of 65.

As a result, the advisory group said, “It was determined that it was appropriate to administer twice as a standard dose that has been confirmed to be effective in the planned clinical trial. However, it is necessary to provide a detailed guideline for the administration interval when using it in the clinical field after approval.” .

“As for whether or not the vaccine is appropriate to the elderly aged 65 or older, the administration to the elderly cannot be excluded just because the number of elderly persons among the participants is small,” he said. “It is acceptable, but nervous system-related including transverse myelitis. Adverse reactions need to be monitored after permission. It is not recommended to administer during pregnancy. In the case of nursing mothers, it is necessary to describe in the precautions for use (permissions), “It is unknown whether this vaccine is secreted into breast milk.” “I do.”

On the other hand, according to the Ministry of Food and Drug Safety, AstraZeneca vaccine showed a prophylactic effect of about 62% in clinical trials after the standard dose (approved dose) was administered twice.

When administered twice, the binding antibody (amount of antibody that binds to the viral antigen) increased 503 times and the neutralizing antibody (antibody that binds to the surface of the virus particle and neutralizes the infectivity of the virus) was increased by 8.5 times.

Abnormal cases that could not be excluded from the vaccine administration included fever and transverse myelitis, and there were no anaphylactic reactions and worsening symptoms of COVID-19.

©’Five-language global economic newspaper’ Ajou Economy. Prohibition of unauthorized reproduction and redistribution

.Source